Research use only. Not for use in diagnostic procedures.

Membrane Target Systems[™]

human Opioid NOP (ORL1) Receptor

Product No.:	6110540400UA

Lot No.: 2668304

Material Provided

Membranes:	1 x 400 units / 400 μL frozen aliquot
Product Information	
Cellular Background:	CHO-K1
GenBank Accession Number:	NM_000913
Unit Size:	2 μg protein / unit
Storage Buffer:	50 mM Tris-HCL (pH 7.4), 0.5mM EDTA, 10mM MgCl_2, 10% sucrose.
Storage Conditions:	Store at -80°C. Freeze-thaw is not recommended as it can affect product performance and homogeneity. In order to minimize negative impact of freeze-thawing, flash freeze in liquid nitrogen for 30 seconds prior to transferring to -80°C.
Stability:	This product is stable for at least 3 years from reception if used and stored under recommended conditions.

Quality Control

 B_{max} and K_d are determined using radioactive saturation binding assays (Figure 1). Protein concentration is determined using the BCA method ⁽¹⁾. Ratio-to-Reference (RTR) is determined by dividing the maximal signal of the current lot (Bmax in fmoles) by the maximal signal of a pre-defined reference tested in parallel. RTR is an indicator of lot-to-lot consistency. *We certify that these results meet our quality release criteria.

Ratio-to-Reference (RTR):	0.57
Expression Level (B _{max}):	4.1 pmol/mg membrane protein.
K_d for [¹²⁵ I]-Nociceptin:	0.02 nM
Protein Concentration:	2 µg/µL

(1) Smith, P.K., et al. (1985). Anal. Biochem. 150, 76-85.



Recommended Assay Conditions

Assay Buffer:	50 mM Tris-HCl pH 7.4, 10 mM MgCl_2, 1 mM EDTA , 0.1% BSA
Wash Buffer:	50 mM Tris-HCl pH 7.4
Binding Protocol:	Binding assays are performed in 200 μL total volume according to the following conditions:
1 - Membrane dilution:	0.05 mL of membranes + 7.45 mL assay buffer (1:150 dilution)
2 - Incubation:	25 μL of incubation buffer or Nociceptin (Bachem H-3036) 1 μM final for non-specific binding (Saturation binding assay)
	For competition binding assay: 25 μL of reference compounds at decreasing concentrations (see figure 2)
	25 μL of radioligand at the appropriate concentration (see graph below) 150 μL of diluted membranes
3 - Incubation time:	60 minutes at 27 °C
4 - Filtration:	aspirate and wash 9 x 500 μL with ice cold wash buffer over GF/C filter (presoaked in 50 mM Tris-HCl pH 7.4, 10 mM MgCl_2, 1 mM EDTA , 0.1% BSA, 0.3% PEI).

Lot Specific Data




Figure 1: Saturation binding assay curve (filtration) 96-well saturation binding assay curve (2 µg membranes/well, TopCount®) using [¹²⁵I]-Nociceptin (Revity NEX338 Lot No.: HV30600)



Typical Product Data




Figure 2: Competition binding assay curve (filtration) 96-well competition binding assay curve (2 µg membranes/well, TopCount®). Recommended radioligand concentration = 0.03 nM.

*Even though two sites can be observed occasionally with some ligands, the data presented is derived from single site fitting.

Reference Compounds	Ki
	(nM)
Nociceptin	0.16
Nociceptin (1-13) amide	0.09
Dynorphin A (1-13) (porcine)	10.4

This product is not for resale or distribution except by authorized distributors. The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

revvity

Revvity 940 Winter Street Waltham, MA 02451 USA

(800) 762-4000 www.revvity.com

For a complete listing of our global offices, visit <u>www.revvlty.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.